With granular insights from early discovery and preclinical efforts through to the optimization of clinical and manufacturing strategies, it’s your one-stop shop to benchmark against competitors, challenges in efficacy, cost-effectiveness, and safety, and hear the latest clinical data poised to shape the field. Plus, in-depth discussions and data-driven case studies showcase the breadth of modalities in development, from RNA, Peptide, and DNA through to Viral and Cellular, enabling you to gain cross-modality learnings to improve your vaccine’s efficacy at the tumor level and ensure you select the right neoantigen type to set your vaccine up for success.

Join 80+ CXOs, VPs, and Directors of Oncology, Immunotherapy, and Vaccine R&D from the field’s leading biopharma organizations to gain the insights and partners you require to translate your personalized vaccines into robust clinical candidates and commercially viable products for multiple tumor types.